Rahul Singhvi

Rahul Singhvi founded National Resilience, Inc. in 2020, where he worked as CO-Chief Executive Officer & Director from 2020 to 2025.
Dr. Singhvi also founded Axella Solutions LLC, where he is working as Managing Partner, Resilience Biotechnologies, Inc., where he is working as Chief Executive Officer, and Axella Biosciences, Inc., where he is working as President, Secretary, Treasurer & Director.
Dr. Singhvi also currently works at Swiftscale Biologics, Inc., as Chief Executive Officer, Codexis, Inc., as Independent Director from 2022, Stratus Therapeutics, Inc., as Director, Kairos Pharma Ltd., as Independent Director from 2024, Tag1 Consulting, Inc., as Director from 2024, and Keck Graduate Institute of Applied Life Sciences, as Trustee.
Dr. Singhvi also formerly worked at Novavax, Inc., as President & Chief Executive Officer from 2005 to 2011, Merck & Co., Inc., as Director-Manufacturing Division from 1999 to 2004, ImmunoCellular Therapeutics Ltd., as Lead Independent Director from 2011 to 2018, NewGen BioPharma Corp., as Director, Univercells SA, as Director, Valor Biotherapeutics LLC, as Director, Magnum Hunter Resources, Inc., as Chief Operating Officer, Bill, Hillary & Chelsea Clinton Foundation, as Member, Ring Therapeutics, Inc., as President from 2019 to 2020, Caliber Biotherapeutics LLC, as Managing Partner, Takeda Vaccines, Inc., as Chief Operating Officer, Flagship Pioneering, LLC, as Operating Partner from 2019 to 2020, Takeda Pharmaceutical Co., Ltd., as Chief Operating Officer from 2013 to 2019, and Flagship Pioneering, LLC, as Partner.
Dr. Singhvi received his graduate degree and doctorate degree from Massachusetts Institute of Technology, undergraduate degree from Indian Institute of Technology Kanpur, and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.